Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

NICE releases draft guidance for using cannabis-based medicinal products

6
SHARES

The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.

The UK National Institute for Health and Care Excellence (NICE) has released draft recommendations for the use of cannabis-based medicinal products. The guide is a result of a comprehensive evaluation of their clinical and cost-effectiveness.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The draft follows the re-classification of these products last year to allow specialist doctors to prescribe them where the needs of patients cannot be met by licensed medicines. The guidance is for the treatment of patients with intractable nausea and vomiting as a result of chemotherapy, chronic pain, spasticity and severe treatment-resistant epilepsy.

The recommendations investigate most cannabis-based medicinal products, including the Sativex, a licensed product for treating spasticity in people with multiple sclerosis (MS). It found that this product is not cost-effective so should not be prescribed for this therapy.  

The draft also says that, other than cannabidiol (CBD) used on its own in the context of a clinical trial, no cannabis-based medicinal products should be used for treating chronic pain. This is because the benefits they offer are very small compared with their high costs and so they can’t be considered a cost-effective use of NHS resources.

Paul Chrisp, director of the Centre for Guidelines at NICE, said: “In most cases, the draft guidance recommends that more research is carried out, echoing the recent call by the National Institute of Health Research for research proposals for these products. To that end NICE welcomes the recent suggestion from the House of Commons Health and Social Care Committee that companies should be encouraged to undertake or enable research into their medicinal cannabis products.”

The UK National Health Service (NHS) has also published a review aimed at assessing the barriers of prescribing cannabis-based medicinal products where safe and clinically appropriate.

This guide highlights the lack of clinical evidence about the long-term safety and effectiveness of medicinal cannabis. It suggests two clinical trials to test cannabis-based products.

The draft guidance will be open for public consultation until 5 September 2019.

Share via
Share via